- Von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG,
Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV
vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
Vaccine. 2018; 36(2): 313-321.
2. Chantratita W, Song KS, Gun Ho C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G,
Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD. 6 HCV genotyping 9G test
and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus
genotyping. J Virol Methods. 2017; 239: 1-8.
3. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S, Houchen CW.
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor
xenografts. J Virol. 2011; 85(23): 12292-12303.
4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global
distribution and prevalence of hepatitis C virus genotypes. Hepatol. 2015; 61(1): 77-87.
5. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med. 2001; 345(1): 41-52.
6. Bennett JE, Dolin R, Blaser MJ. Principles and practice of infectious diseases. Elsevier Health
Sci; 2014; 1: 1336-1356.
7. Ranjith-Kumar CT, Kao CC. Biochemical activities of the HCV NS5B RNA-dependent RNA
polymerase. Hepatitis C viruses: Genomes and molecular biology. Norfolk (UK): Horizon
Bioscience. 2006: 293-310.
8. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection.
Therap Adv Gastroenterol. 2010; 3(3): 191-202.
9. Motawi TM, Rizk SM, Shaker OG, Mokhtar OZ. MicroRNAs as predictor markers for response
to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients. PloS one. 2015; 10
(3): 1-12.
10. Castilho MC, Martins AN, Horbach IS, Perez RD, Figueiredo FA, Pinto PD, Nabuco LC, Lima
DB, Tanuri A, Porto LC, Júnior F. Association of hepatitis C virus NS5B variants with resistance
to new antiviral drugs among untreated patients. Mem Inst Oswaldo Cruz. 2011; 106(8):
968-975.
11. Huang T, Wang J, Cai YD, Yu H, Chou KC. Hepatitis C virus network based classification of
hepatocellular cirrhosis and carcinoma. PLoS One. 2012; 7(4): e34460.
12. Hosseini Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian
SM. Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran: a
multicenter study. J Med Virol. 2006; 78(5): 569-573.
13. Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its
significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect
Dis. 2008; 61(4): 408-414.
14. Haghshenas MR, Babamahmoodi F, Rafiei AR, Vahedi V. The correlation between HCV
genotypes and liver damage in HCV patients. J Mazandaran Uni Med Sci. 2011; 21(85): 76-83.
15. Samimi Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of
hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol.
2004; 74(2): 246-252.
16. Makhloogh A, Aezinia N, Haghshenas MR, Tirgar-fakheri H, Maleki I, Taghvaei T.
Comparison of Hepatitis C Virus Genotypes in Hemodialysis and Nonuremic Patients.
Armaghane Danesh. 2010; 15(3): 283-292. [In Persian]
17. Hejazi MS, Ghotaslou R, Farshdoosty Hagh M, Mohammadzadeh Sadigh Y. Genotyping of
hepatitis C virus in northwest of Iran. Biotechnol. 2007; 6(3): 302-308.
18. Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of
amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral
isolates and comparison with worldwide isolates. Virol J. 2012; 9(1): 214.
19. Kim DW, Lee SA, Kim H, Won YS, Kim BJ. Naturally occurring mutations in the
nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients
chronically infected with HCV genotype 1b. PLOS One. 2014; 9(1): e87773.
20. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F.
Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B
polymerase in DAA treatment-naive patients. Virol J. 2013; 10(1): 355.
|
